Tiberend Strategic Advisors, Inc. is a full service investor and corporate communications firm specializing in the healthcare and life sciences industry. Founded in 1989, Tiberend’s mission is to provide expert public and investor relations counsel to companies along the entire development lifecycle, from emerging, clinical-stage to publicly traded, revenue generating. In doing so, Tiberend creates individualized platforms for companies to communicate their value proposition to those audiences that have the greatest influence on their growth and success - investors, industry stakeholders, customers and the media.
Tiberend Strategic Advisors, Inc.的外部链接
35 W. 35th Street
11th Floor
US，NY，New York，10001-0080
Tiberend Strategic Advisors, Inc.转发了
Did you know that close to 50% of patients treated with #antidepressants experience inadequate relief? Enveric Biosciences, Inc. is developing novel #neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders #mentalhealth $ENVB https://www.enveric.com/
Atossa Therapeutics, Inc. CEO Steven Quay MD, PhD, was featured in Drug Delivery Leader thanks to Tom von Gunden. The discussion covers formulations, coatings, and dosing for orally administered, cancer-preventative approaches to reducing breast density.
Elysium Therapeutics, Inc. co-founder & CSO Tom Jenkins, Ph.D., is featured in Life Science Leader.
Lisa Ricciardi, President and CEO of Cognition Therapeutics, Inc. (Nasdaq: CGTX), was a guest on Benzinga's All-Access. Cognition Therapeutics is a neuroscience company that is developing oral medications to treat neurodegenerative disorders, with recent breakthroughs in the treatment of dementia with Lewy bodies (DLB) and Alzheimer's disease. https://lnkd.in/gasFEJ9B
Tiberend Strategic Advisors, Inc.转发了
CEO Lisa Ricciardi discuss with Benzinga the plan to bring #zervimesine (CT1812) to market including the business development process currently in place. Watch Lisa’s full interview here: https://lnkd.in/gj4vgAxE #LewyBodyDementia #LBDAwareness #LewyStrong #dementia #BiotechInnovation #ClinicalResearch #ClinicalTrial #DementiaWithLewyBodies #biotech #AlzheimersDisease #CT1812 #biomarkers
Tiberend Strategic Advisors, Inc.转发了
Francisco Salva, CEO of Azitra Inc., delves into the innovative strategies employed by the company in treating skin diseases. Azitra leads the way in utilizing engineered living organisms to combat rare conditions such as Netherton syndrome and ichthyosis vulgaris. By leveraging cutting-edge technologies like artificial intelligence, Azitra aims to establish novel benchmarks in dermatological care. Francisco sheds light on Azitra's distinctive approaches, ongoing clinical trials, and the intricacies faced within this specialized domain. 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/d4WjsKgV